GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Easywell Biomedicals Inc (ROCO:1799) » Definitions » Debt-to-EBITDA

Easywell Biomedicals (ROCO:1799) Debt-to-EBITDA : 15.24 (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Easywell Biomedicals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Easywell Biomedicals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$221.8 Mil. Easywell Biomedicals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$342.5 Mil. Easywell Biomedicals's annualized EBITDA for the quarter that ended in Dec. 2024 was NT$37.0 Mil. Easywell Biomedicals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 15.24.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Easywell Biomedicals's Debt-to-EBITDA or its related term are showing as below:

ROCO:1799' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.52   Med: -2   Max: 44.25
Current: 44.25

During the past 13 years, the highest Debt-to-EBITDA Ratio of Easywell Biomedicals was 44.25. The lowest was -4.52. And the median was -2.00.

ROCO:1799's Debt-to-EBITDA is ranked worse than
98.22% of 674 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs ROCO:1799: 44.25

Easywell Biomedicals Debt-to-EBITDA Historical Data

The historical data trend for Easywell Biomedicals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Easywell Biomedicals Debt-to-EBITDA Chart

Easywell Biomedicals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.68 -3.94 -4.14 -4.52 44.25

Easywell Biomedicals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.99 -3.13 26.04 3.45 15.24

Competitive Comparison of Easywell Biomedicals's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Easywell Biomedicals's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Easywell Biomedicals's Debt-to-EBITDA falls into.


;
;

Easywell Biomedicals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Easywell Biomedicals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(221.82 + 342.464) / 12.753
=44.25

Easywell Biomedicals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(221.82 + 342.464) / 37.032
=15.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Easywell Biomedicals  (ROCO:1799) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Easywell Biomedicals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Easywell Biomedicals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Easywell Biomedicals Business Description

Traded in Other Exchanges
N/A
Address
No.10, Yanfa 2nd Road, Hsinchu Science Park, 1st floor, Hsinchu, TWN, 30076
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients and over-the-counter drug products The company's segment include the Drug development segment and Other segments.

Easywell Biomedicals Headlines

No Headlines